Abstract:Medulloblastoma (MB) is a highly aggressive and the most common brain tumor in childhood. MB presents a high intertumoral heterogeneity, with at least four molecular subgroups identified (SHH, WNT, Group 3, and Group 4). Metastatic MB, or Leptomeningeal Disease (LMD), is predominantly found in the MB Group 3 type. Although LMD represents a main clinical challenge, its molecular mechanisms remain poorly characterized. Recent research has shown that primary and MB metastasis diverge dramatically. Our work has focused on establishing therapy naïve Group 3 Patient-Derived Xenografts models of primary and metastatic Medulloblastoma to conduct transcriptomic profiling at the bulk and single-nuclei RNAseq levels to identify genetic drivers/pathways that sustain leptomeningeal disease compartment. Our results show various signaling pathways enriched across LMD models, such as MYC targets, unfolded protein response, and fatty acid metabolism. Using single-sample GSEA analysis (ssGSEA) and deconvolution approaches, we have also identified that our PDXes models retain neoplastic subpopulations previously identified in MB single-cell sequencing studies. Similarly, we have identified slight differences in cell subpopulation proportions between primary and leptomeningeal compartments. Our single-nuclei studies have confirmed these results and differentially expressed genes previously found in bulk RNAseq analyses. These results suggest the presence of cell populations enriched in the metastatic compartment with an aberrant transcription phenotype and adaptations in fatty acid metabolism to survive the leptomeningeal space. In conclusion, our work supports the notion that primary and LMD retain subpopulation clusters present in MB Group 3 tumors with different proportions in the metastatic compartment shown by bulkRNAseq deconvolution and single nuclei RNA analysis. We also show that primary and LMD are transcriptionally different, with various enriched pathways in the metastatic compartment and shared among LMD Group 3 PDX models. Through these approaches, we aim to elucidate the genetic dependencies of metastatic Medulloblastoma that will help for targeted therapies.

Examining the Biomarkers and Molecular Mechanisms of Medulloblastoma Based on Bioinformatics Analysis

Identification of Core Genes and Pathways in Medulloblastoma by Integrated Bioinformatics Analysis

Identification of PBK As a Hub Gene and Potential Therapeutic Target for Medulloblastoma.

Identification and validation of a metabolism-related gene signature for predicting the prognosis of paediatric medulloblastoma

Metabolomic profiling of childhood medulloblastoma: contributions and relevance to diagnosis and molecular subtyping

Prognostic Significance of MicroRNAs in Medulloblastoma: A Systematic Review and Meta-Analysis

Gene Expression of Growth Signaling Pathways is Up-Regulated in CD133-positive Medulloblastoma Cells.

Identify Signature Regulatory Network for Glioblastoma Prognosis by Integrative Mrna and Mirna Co-Expression Analysis.

Comprehensive Analysis of a Microrna Expression Profile in Pediatric Medulloblastoma.

The Expression of PI 3 K , AKT , Β-Catenin and VEGFR 2 in Medulloblastoma

Subgroup-Specific Diagnostic, Prognostic, and Predictive Markers Influencing Pediatric Medulloblastoma Treatment

Identification of Key Candidate Genes and Pathways in Glioblastoma by Integrated Bioinformatical Analysis

Medulloblastoma: Molecular understanding, treatment evolution, and new developments

Integrative Analysis of Gene Expression and DNA Methylation Through One‐class Logistic Regression Machine Learning Identifies Stemness Features in Medulloblastoma

Identification Of Prognostic Genes In Paediatric Medulloblastoma From Mrna Expression Profiles

Epco-57. Integrated Analysis Of Bulk And Single-Cell Rna Sequencing Data Of Primary And Metastatic Pediatric Medulloblastoma

An Immune Microenvironment-Associated Gene Signature Predicts Outcomes and Therapeutic Response in Pediatric Medulloblastoma

Identification of Core Genes and Screening of Potential Targets in Glioblastoma Multiforme by Integrated Bioinformatic Analysis

Identification of potential biomarkers and candidate small molecule drugs in glioblastoma

In-depth Inference of Transcriptional Regulatory Networks Identifies NPM1 as a Druggable Master Regulator in Medulloblastoma

Single‐Cell Chromatin Accessibility Analysis Reveals Subgroup‐Specific TF‐NTR Regulatory Circuits in Medulloblastoma